Free Trial

Embecta (EMBC) Competitors

Embecta logo
$14.25 -0.05 (-0.35%)
Closing price 10/22/2025 04:00 PM Eastern
Extended Trading
$13.94 -0.31 (-2.18%)
As of 10/22/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EMBC vs. LIVN, WRBY, INSP, EYE, LQDA, LMAT, AORT, PRCT, ENOV, and CDRE

Should you be buying Embecta stock or one of its competitors? The main competitors of Embecta include LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), National Vision (EYE), Liquidia Technologies (LQDA), LeMaitre Vascular (LMAT), Artivion (AORT), PROCEPT BioRobotics (PRCT), Enovis (ENOV), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.

Embecta vs. Its Competitors

Embecta (NASDAQ:EMBC) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Embecta has a net margin of 7.58% compared to LivaNova's net margin of -16.13%. LivaNova's return on equity of 14.57% beat Embecta's return on equity.

Company Net Margins Return on Equity Return on Assets
Embecta7.58% -23.40% 14.46%
LivaNova -16.13%14.57%6.91%

Embecta presently has a consensus price target of $19.00, suggesting a potential upside of 33.33%. LivaNova has a consensus price target of $59.71, suggesting a potential upside of 8.87%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than LivaNova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Embecta
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
LivaNova
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Embecta has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Embecta$1.12B0.74$78.30M$1.439.97
LivaNova$1.25B2.39$63.23M-$3.89-14.10

93.8% of Embecta shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 0.4% of Embecta shares are held by company insiders. Comparatively, 0.3% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Embecta has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

In the previous week, LivaNova had 3 more articles in the media than Embecta. MarketBeat recorded 4 mentions for LivaNova and 1 mentions for Embecta. Embecta's average media sentiment score of 1.79 beat LivaNova's score of 1.73 indicating that Embecta is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Embecta
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
LivaNova
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Embecta beats LivaNova on 9 of the 16 factors compared between the two stocks.

Get Embecta News Delivered to You Automatically

Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EMBC vs. The Competition

MetricEmbectaMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$836.34M$8.51B$6.16B$10.67B
Dividend Yield4.20%2.11%5.72%4.86%
P/E Ratio9.9775.6429.0927.13
Price / Sales0.7439.65582.26126.20
Price / Cash4.2921.5437.1261.42
Price / Book-1.117.0712.146.43
Net Income$78.30M$250.93M$3.33B$276.63M
7 Day Performance4.09%-0.74%-0.76%-0.77%
1 Month Performance-2.20%-2.99%5.30%0.68%
1 Year Performance1.64%12.92%67.61%32.03%

Embecta Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EMBC
Embecta
4.7139 of 5 stars
$14.25
-0.3%
$19.00
+33.3%
+0.6%$836.34M$1.12B9.972,100Positive News
LIVN
LivaNova
2.8371 of 5 stars
$51.78
+2.2%
$59.71
+15.3%
+2.9%$2.77B$1.25B-13.312,900Positive News
WRBY
Warby Parker
2.308 of 5 stars
$22.17
-0.4%
$24.75
+11.7%
+22.6%$2.34B$821.35M-316.613,780
INSP
Inspire Medical Systems
4.8199 of 5 stars
$77.57
+3.2%
$150.50
+94.0%
-58.7%$2.22B$802.80M44.841,246Positive News
EYE
National Vision
2.6688 of 5 stars
$26.37
+3.2%
$24.73
-6.2%
+165.5%$2.02B$1.82B-146.5013,411
LQDA
Liquidia Technologies
3.6059 of 5 stars
$23.77
+2.5%
$32.38
+36.2%
+99.5%$2.00B$14M-13.9850Analyst Forecast
LMAT
LeMaitre Vascular
3.3844 of 5 stars
$85.31
-0.9%
$97.60
+14.4%
+3.2%$1.95B$219.86M41.41490
AORT
Artivion
2.6875 of 5 stars
$40.63
+1.1%
$43.97
+8.2%
+63.7%$1.90B$405.04M-96.741,600
PRCT
PROCEPT BioRobotics
2.8296 of 5 stars
$33.00
+0.2%
$70.00
+112.1%
-48.5%$1.83B$224.50M-21.29430Upcoming Earnings
ENOV
Enovis
3.6924 of 5 stars
$29.76
+0.2%
$51.00
+71.4%
-18.2%$1.70B$2.19B-2.097,367
CDRE
Cadre
3.1728 of 5 stars
$39.03
+1.7%
$37.50
-3.9%
+9.2%$1.56B$572.61M41.522,284Dividend Announcement

Related Companies and Tools


This page (NASDAQ:EMBC) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners